MET and non-small cell lung carcinoma: Tepotinib underwent further evaluation in patients with tumors with MET alterations, including NSCLC with METex14 skipping or high-level METamp (16, 65), EGFR-mutant NSCLC with MET-driven resistance to EGFR inhibitors (66), and MET-overexpressing advanced HCC (67, 68).